Terns Pharmaceuticals, Inc.
TERNNASDAQHealthcare
$52.95
$-0.02(-0.03%)
Market Cap$4.8B
P/E Ratio—
52W High$53.19
52W Low$2.655
Terns Pharmaceuticals, Inc.（TERN）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · TERN · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $1.02B | $0.36B | $0.26B | $0.28B | $0.17B |
| Net Receivables | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Inventory | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Assets | $1.02B | $0.36B | $0.27B | $0.29B | $0.17B |
| PP&E Net | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $1.03B | $0.36B | $0.27B | $0.29B | $0.17B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Liabilities | $0.02B | $0.02B | $0.01B | $0.01B | $0.01B |
| Long-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Liabilities | $0.02B | $0.02B | $0.01B | $0.01B | $0.01B |
| Stockholders Equity | |||||
| Retained Earnings | ($0.52B) | ($0.42B) | ($0.33B) | ($0.24B) | ($0.18B) |
| Total Stockholders Equity | $1.01B | $0.35B | $0.26B | $0.28B | $0.16B |
| Total Liab & Equity(computed) | $1.03B | $0.36B | $0.27B | $0.29B | $0.17B |
| Debt Summary | |||||
| Total Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Debt | ($0.52B) | ($0.16B) | ($0.08B) | ($0.14B) | ($0.05B) |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Terns Pharmaceuticals, Inc.
关于Terns Pharmaceuticals, Inc.（TERN）资产负债表
Terns Pharmaceuticals, Inc.总资产$1.03B，现金及短期投资$1.02B，总负债$0.02B，总债务$0.00B，股东权益$1.01B。
常见问题
TERN · 4 问Terns Pharmaceuticals, Inc.总债务$0.00B，净债务($0.52B)。
TERN total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10